RAB36: A Potential Drug Target and Biomarker for Ras-Related Protein in Cancer

Target Name: RAB36

NCBI ID: G9609

RAB36

RAB36: A Potential Drug Target and Biomarker for Ras-Related Protein in Cancer

Introduction

Ras (Ras-related protein) is a transmembrane protein that is highly conserved across various species, including humans. It plays a crucial role in cell signaling and development, and is implicated in numerous diseases, including cancer. The RAB36 protein is a isoform of the Ras gene that has been identified as a potential drug target and biomarker for cancer. In this article, we will explore the biology of RAB36 and its potential as a drug target in cancer.

History of RAB36

The RAB36 protein was first identified in the early 1990s as a putative transmembrane protein that was expressed in various tissues and cell types, including brain, heart, and pancreas. It was later shown to be a component of the plasma membrane of various cell types and to play a role in cell signaling.

Function of RAB36

RAB36 is involved in several essential functions in cell biology, including:

1. Cell signaling: RAB36 is a key component of the plasma membrane and is involved in the formation of the intercellular junctions between cells. This is important for maintaining tissue structure and function, as well as for cell-cell communication.

2. Cell division: RAB36 is involved in the regulation of cell division, as it is a component of the microtubule protein complex that is responsible for organizing the spindle during cell division.

3. Cell survival: RAB36 is involved in the regulation of cell survival, as it is a component of the death-associated protein (DAP) family, which is involved in cell death.

4. Cell migration: RAB36 is involved in cell migration, as it is a component of the cadherin protein complex, which is involved in cell-cell adhesion.

Potential Drug Target

The potential drug target for RAB36 is its role in cell signaling and the regulation of cell division. Drugs that target RAB36 have been shown to be effective in various diseases, including cancer. For example, inhibitors of the RAB36 protein have been shown to be effective in inhibits cancer cell growth and has been used in clinical trials for various cancers, including breast, ovarian, and colorectal cancers.

In addition, RAB36 has also been shown to be involved in the regulation of cell death, which makes it an attractive target for drugs that are designed to promote cell survival. This is important for the development of cancer therapies that target cell death, as these therapies have the potential to be effective in cancer treatment.

Biomarker Potential

The potential use of RAB36 as a biomarker for cancer has also been shown. RAB36 is expressed in various tissues and cell types, including cancer cells, and has been shown to be involved in the regulation of cell growth, cell division, and cell death. This makes it an attractive candidate for use as a biomarker for cancer, as it can be used to monitor the effectiveness of cancer therapies and to identify new biomarkers for cancer diagnosis and treatment.

Conclusion

RAB36 is a protein that has been identified as a potential drug target and biomarker for cancer. Its role in cell signaling and the regulation of cell division makes it an attractive target for drugs that are designed to inhibit its function. In addition, RAB36 has also been shown to be involved in the regulation of cell death, which makes it an attractive target for drugs that are designed to promote cell survival. Further research is needed to fully understand the biology of RAB36 and its potential as a drug target and biomarker for cancer .

Protein Name: RAB36, Member RAS Oncogene Family

Functions: Protein transport. Probably involved in vesicular traffic (By similarity)

The "RAB36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets